SEARCH

SEARCH BY CITATION

LITERATURE CITED

  • 1
    Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. World Health Organisation classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC, Geneva, Switzerland: WHO Press; 2008.
  • 2
    Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:54465456.
  • 3
    Sarfati M. Interleukin-4 and the two isoforms of CD23 antigen: Their possible contribution to the physiopathology of chronic lymphocytic leukemia disease. Nouv Rev Fr Hematol 1993;35:109113.
  • 4
    Fournier S, Delespesse G, Rubio M, Biron G, Sarfati M. CD23 antigen regulation and signaling in chronic lymphocytic leukemia. J Clin Invest 1992;89:13121321.
  • 5
    Lüdin C, Hofstetter H, Sarfati M, Levy CA, Suter U, Alaimo D, Kilchherr E, Frost H, Delespesse GCloning and expression of the cDNA coding for a human lymphocyte IgE receptor. EMBO J 1987;6:109114.
  • 6
    Fournier S, Tran ID, Suter U, Biron G, Delespesse G, Sarfati M. The in vivo expression of type B CD23 mRNA in B-chronic lymphocytic leukemic cells is associated with an abnormally low CD23 upregulation by IL-4: Comparison with their normal cellular counterparts. Leuk Res 1991;15:609618.
  • 7
    Delespesse G, Sarfati M, Hofstetter H. Human IgE-binding factors. Immunol Today 1989;10:159164.
  • 8
    Sarfati M, Fournier S, Wu CY, Delespesse G. Expression, regulation and function of human Fc epsilon RII (CD23) antigen. Immunol Res 1992;11:260272.
  • 9
    Sarfati M. CD23 and chronic lymphocytic leukemia. Blood Cells 1993;19:591599.
  • 10
    Sarfati M, Bron D, Lagneaux L, Fonteyn C, Frost H, Delespesse G. Elevation of IgE-binding factors in serum of patients with B cell-derived chronic lymphocytic leukemia. Blood 1988;71:9498.
  • 11
    Fournier S, Rubio M, Delespesse G, Sarfati M. Role for low-affinity receptor for IgE (CD23) in normal and leukemic B-cell proliferation. Blood 1994;84:18811886.
  • 12
    Sarfati M, Chevret S, Chastang C, Biron G, Stryckmans P, Delespesse G, Binet JL, Merle-Beral H, Bron D. Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia. Blood 1996;88:42594264.
  • 13
    Saka B, Aktan M, Sami U, Oner D, Sanem O, Dinçol G. Prognostic importance of soluble CD23 in B-cell chronic lymphocytic leukemia. Clin Lab Haematol 2006;28:3035.
  • 14
    Meuleman N, Stamatopoulos B, Dejeneffe M, El Housni H, Lagneaux L, Bron D. Doubling time of soluble CD23: A powerful prognostic factor for newly diagnosed and untreated stage A chronic lymphocytic leukemia patients. Leukemia 2008;22:18821890.
  • 15
    Castillo L, Maccallum DM. Cytokine measurement using cytometric bead arrays. Methods Mol Biol 2012;845:425434.
  • 16
    Elshal MF, McCoy JP. Multiplex bead array assays: Performance evaluation and comparison of sensitivity to ELISA. Methods 2006;38:317323.
  • 17
    Mossalayi MD, Arock M, Delespesse G, Hofstetter H, Bettler B, Dalloul AH, Kilchherr E, Quaaz F, Debré P, Sarfati M. Cytokine effects of CD23 are mediated by an epitope distinct from the IgE binding site. EMBO J 1992;11:317323.
  • 18
    Sarfati M, Bettler B, Letellier M, Fournier S, Rubio-Trujillo M, Hofstetter H, Delespesse GNative and recombinant soluble CD23 fragments with IgE suppressive activity. Immunology 1992;76:662667.
  • 19
    Rector E, Nakajima T, Rocha C, Duncan D, Lestourgeon D, Mitchell RS, Fischer J, Sehon AH, Delespesse GDetection and characterization of monoclonal antibodies specific to IgE receptors on human lymphocytes by flow cytometry. Immunology 1985;55:481488.
  • 20
    Rogala B, Rymarczyk B. Soluble CD23 in allergic diseases. Arch Immunol Ther Exp (Warsz) 1999;47:251255.
  • 21
    Sayinalp S, Akalin S, Sayinalp N, Erbas T, Bayraktar M, Ozcebe OI, Dündar S, Kirazli S. Serum immunoglobulin E and soluble CD23 in patients with Graves' disease. Horm Metab Res 1996;28:133137.
  • 22
    Hallek M, Langenmayer I, Nerl C, Knauf W, Dietzfelbinger H, Adorf D, Ostwald M, Busch R, Kuhn-rcia-ManeroHallek I, Thiel E, et al. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood 1999;93:17321737.
  • 23
    Knauf WU, Langenmayer I, Ehlers B, Mohr B, Adorf D, Nerl CH, Hallek M, Zwingers TH, Emmerich B, Thiel ESerum levels of soluble CD23, but not soluble CD25, predict disease progression in early stage B-cell chronic lymphocytic leukemia. Leuk Lymphoma 1997;27:523532.
  • 24
    Hallek M, Wanders L, Strohmeyer S, Emmerich B. Thymidine kinase: A tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications. Ann Hematol 1992;65:15.
  • 25
    Zenz T, Mertens D, Küppers R, Döhner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010;10:3750.
  • 26
    Cramer P, Hallek M. Prognostic factors in chronic lymphocytic leukemia-what do we need to know? Nat Rev Clin Oncol 2011;8:3847.
  • 27
    Giordano Attianese GM, Marin V, Hoyos V, Savoldo B, Pizzitola I, Tettamanti S, Agostoni V, Parma M, Ponzoni M, Bertilaccio MT, et al. In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor. Blood 2011;117:47364745.
  • 28
    Alatrash G, Albitar M, O'Brien S, Wang X, Manshouri T, Faderl S, Ferrajoli A, Burger J, Garcia-Manero G, Kantarjian HM, et al. Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR). Br J Haematol 2010;148:386393.
  • 29
    Manshouri T, Do KA, Wang X, Giles FJ, O'Brien SM, Saffer H, Thomas D, Jilani I, Kantarjian HM, Keating MJ, et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 2003;101:25072513.